LivaNova PLC (NASDAQ:LIVN) Shares Purchased by Two Sigma Investments LP

Two Sigma Investments LP increased its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 27.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 439,582 shares of the company's stock after purchasing an additional 93,985 shares during the quarter. Two Sigma Investments LP owned 0.81% of LivaNova worth $20,357,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in LIVN. Russell Investments Group Ltd. lifted its stake in LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after purchasing an additional 219 shares during the last quarter. Sterling Capital Management LLC lifted its stake in LivaNova by 800.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock worth $75,000 after purchasing an additional 1,441 shares during the last quarter. Vestcor Inc bought a new position in LivaNova during the fourth quarter worth $204,000. Optimize Financial Inc bought a new position in LivaNova during the fourth quarter worth $208,000. Finally, Corton Capital Inc. bought a new position in LivaNova during the fourth quarter worth $214,000. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Needham & Company LLC reiterated a "buy" rating and issued a $64.00 target price on shares of LivaNova in a research note on Tuesday, May 13th. Stifel Nicolaus cut their target price on LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Robert W. Baird raised their target price on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Wall Street Zen cut LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, Barclays cut their target price on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $59.29.

LivaNova Stock Performance

Shares of NASDAQ LIVN traded up $1.66 during midday trading on Tuesday, reaching $43.54. 125,671 shares of the company traded hands, compared to its average volume of 649,130. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $61.94. The stock has a 50-day moving average price of $38.79 and a 200 day moving average price of $44.48. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market cap of $2.37 billion, a price-to-earnings ratio of 103.71 and a beta of 0.84.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.